Acutus Goes Public To Compete With Established Electrophysiology Players
The IPO is expected to raise $166m to support R&D of new arrhythmia mapping and ablation technologies and expand commercial operations.
You may also be interested in...
Exec Chat: Steven Mickelsen Helps Acutus Translate Science Into Improved Outcomes
Mickelsen, an electrophysiologist at the University of Iowa, recently joined the rapidly growing San Diego-area company as Chief Translational Science Officer and is helping to guide the company’s development of novel electrophysiology therapies to treat cardiac arrhythmias.
J&J, Acutus And Boston Scientific Announce Plans For Pulsed Field AF-Ablation Technologies
Pulsed field ablation, which uses a controlled electrical field instead of focused heat or cold, has shown promise as a safer alternative to thermal and cryo approaches for atrial fibrillation ablation.
IPOs Are Back: Liquid Biopsy, Cardio, Dialysis Firms Lead $1.5Bn Charge
Who wants to go public during a once-in-a-century crisis? It seems like quite a few medtechs do.